Bank Of America Corp Macrogenics Inc Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Macrogenics Inc stock. As of the latest transaction made, Bank Of America Corp holds 119,759 shares of MGNX stock, worth $520,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,759

Previous 310,900 61.48%

Holding current value

$520,951

Previous $4.58 Million 88.9%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.31 - $18.51 $632,676 - $3.54 Million	-191,141 Reduced 61.48%	119,759 $508,000
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $1.65 Million - $3.62 Million	168,482 Added 118.3%	310,900 $4.58 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $204,543 - $461,592	-45,657 Reduced 24.28%	142,418 $1.37 Million
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $37,897 - $61,850	8,203 Added 4.56%	188,075 $1.01 Million
Q1 2023 May 12, 2023	BUY	$4.82 - $7.24 $89,598 - $134,584	18,589 Added 11.53%	179,872 $1.29 Million
Q4 2022 Feb 10, 2023	BUY	$3.34 - $6.98 $230,647 - $482,010	69,056 Added 74.88%	161,283 $1.08 Million
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $118,621 - $205,714	39,409 Added 74.61%	92,227 $319,000
Q2 2022 Aug 12, 2022	SELL	$2.25 - $9.99 $380,191 - $1.69 Million	-168,974 Reduced 76.19%	52,818 $155,000
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $839,275 - $1.75 Million	103,359 Added 87.27%	221,792 $1.95 Million
Q4 2021 Feb 08, 2022	BUY	$15.91 - $21.88 $1.3 Million - $1.79 Million	81,653 Added 222.0%	118,433 $1.9 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $155,156 - $225,582	7,860 Added 27.18%	36,780 $770,000
Q2 2021 Sep 13, 2021	BUY	$20.49 - $35.63 $592,570 - $1.03 Million	28,920 New	28,920 $777,000

Others Institutions Holding MGNX

# of Institutions

149

Shares Held

60.4M

Call Options Held

218K

Put Options Held

259K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $267M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Macrogenics Inc Transaction History